Biotech entity
Against the same-window beat baseline of 16% negative, this entity's 44% share is more negative. Coverage clusters in pharma, which accounts for 6 of those 9, with the remainder spread across 2 other categories. They are less corroborated than the beat average, carrying 2.7 original sources each against 3.5 for the same window.
Last mentioned: 3d ago
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 44 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Against the same-window beat baseline of 16% negative, this entity's 44% share is more negative. Coverage clusters in pharma, which accounts for 6 of those 9, with the remainder spread across 2 other categories. They are less corroborated than the beat average, carrying 2.7 original sources each against 3.5 for the same window. Merck & Co. is most often covered alongside CDC, which appears in 3 of these 9 stories. Across a 183-day span, the pace is roughly 0.3 stories per week. The busiest single day carried 2. The 6 average consequence score is below the beat benchmark of 6.1 in the same window. Merck & Co. appears in 9 tracked Biotech stories published from February 19, 2026 through August 20, 2026.
Computed from the 9 stories linked to this entity, with beat comparisons drawn from all 753 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Merck & Co.. Shared-story counts are live from our verified record — not editorial picks.
Target Deadline
Goal for participating nations to reach the 90-70-90 elimination milestones.
Elimination Target
Deadline for reaching the 90-70-90 vaccination, screening, and treatment goals.
Federal Injunction
A federal judge issues a temporary block on the administration's vaccine agenda, citing public health risks.
Expected Response
The Trump administration is expected to file its initial legal defense regarding executive agency authority.
Fund Launch
Jacinda Ardern officially unveils the dedicated fund for Pacific cervical cancer elimination.
FY 2025 Earnings
Official reporting of full-year financial results and 2026 clinical guidance.
$5.1M Grant Awarded
Major funding secured to scale screening and vaccination across the region.
Public Announcement
Arizona and other state attorneys general publicly detail the health risks associated with the vaccine rollback.
Lawsuit Filed
A coalition of states files a formal complaint against the Trump administration in federal court.
Proposed Schedule Changes
The administration proposes sweeping changes to the national pediatric immunization schedule.
Policy Shift Initiated
RFK Jr. begins implementing a new agenda for federal vaccine oversight and safety reviews.
Cibotercept Data
Anticipated top-line data from the Phase 2 TROPOS trial in PAH patients.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Regional Assessment
Health audits reveal critical gaps in HPV vaccine coverage across the Pacific Islands.
Pilot Programs
Initial HPV self-collection pilots begin in select Pacific island nations.
WHO Global Strategy
WHO launches the global strategy to accelerate the elimination of cervical cancer.
WHO Global Strategy
WHO launches the global strategy to accelerate the elimination of cervical cancer.
Biopharma companies face a growing dose-optimization debate as researchers present evidence that checkpoint inhibitors such as Opdivo and Keytruda can be effective at fractions of FDA-approved doses. Regulatory and commercial models built on fixed dosing face pressure to incorporate dose-ranging data.
Source: edition.cnn.com · freerepublic.com
A federal judge has issued a temporary injunction against Robert F. Kennedy Jr.’s proposed changes to national vaccine policy, citing potential risks to public health. The ruling provides a reprieve for pharmaceutical manufacturers and public health agencies while the legal merits of the administration's agenda are debated.
South Carolina health officials have already allocated $1.6 million to contain a significant measles outbreak that shows no signs of immediate resolution. The expenditure highlights the massive economic burden of vaccine-preventable diseases on state public health infrastructures.
Former New Zealand Prime Minister Jacinda Ardern has launched a dedicated health fund to combat the disproportionately high rates of cervical cancer in Pacific Island nations. The initiative focuses on scaling HPV DNA testing and vaccination programs to meet WHO elimination targets by 2030.
A new $5.1 million grant has been awarded to accelerate cervical cancer elimination efforts across the Pacific region, focusing on HPV vaccination and advanced screening. The initiative aligns with the WHO's global strategy to eradicate the disease through the 90-70-90 targets by 2030.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
California and 14 other states have filed a federal lawsuit against the Trump administration, challenging recent modifications to the recommended childhood immunization schedule. The coalition argues that these changes lack scientific justification and threaten to undermine decades of public health progress.
A coalition of over a dozen states, led by Arizona, has filed a federal lawsuit against the Trump administration to block the rollback of childhood vaccine recommendations. The plaintiffs argue that the changes to CDC guidelines bypass scientific protocols and present an immediate threat to national public health safety.
A landmark study reveals that the excruciating tropical disease Chikungunya is now capable of local transmission across most of Europe. Driven by the northward migration of the Aedes albopictus mosquito, this shift creates an urgent demand for vaccines and diagnostic infrastructure in previously unaffected regions.
Source: theguardian.com · aol.co.uk
Merck & Co. is linked from 9 stories on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
